Insights into Resistance against Lincosamide Antibiotics  by Sundlov, Jesse A. & Gulick, Andrew M.
Structure
PreviewsInsights into Resistance
against Lincosamide Antibiotics
Jesse A. Sundlov1 and Andrew M. Gulick1,*
1Department of Structural Biology, Hauptman-Woodward Medical Research Institute, State University of New York at Buffalo,
Buffalo, NY, USA
*Correspondence: gulick@hwi.buffalo.edu
DOI 10.1016/j.str.2009.11.001
Bacteria utilize multiple strategies to circumvent antibiotics, producing broad specificity exporters or
enzymes that catalyze the modification of either antibiotics or their targets. A report in this issue of Structure
provides the structural and catalytic mechanisms of LinB, an adenylyltransferase of E. faecium that confers
resistance to the lincosamide antibiotic clindamycin.The emergence of pathogenic bacteria
that are resistant to many commonly
used antibiotics has led to a renewed
interest in understanding the biochemical
basis of antibiotic action and resistance.
Historically, resistant strains have been
identified very soon after the introduction
of a novel compound into the clinical
setting. Resistance develops primarily
from the ability of bacterial export proteins
to rid the cell of the antibiotic by modifica-
tion of the target protein to reduce antibi-
otic activity, or by the production of
specific enzymes that are responsible for
the chemical inactivation of the antibiotic
molecule (Fischbach and Walsh, 2009).
The facility of transferring resistance
factors between organisms and species,
and the evolutionary pressure to do so,
has led to the current state, where multi-
drug-resistant bacteria are posing serious
clinical problems (Nordmann et al., 2007).
With a few notable exceptions, the
development of new antibiotics over the
last few decades has focused primarily
on the chemical modifications of known
antibiotic scaffolds (FischbachandWalsh,
2009). In this process, new compounds
are identified from chemical libraries that
are then screened for efficacy. A more
directed approach involves the rational
design of new compounds while simulta-
neously considering effectiveness and
resistance. This prospect of true struc-
ture-guided antibiotic design, however,
relies on a clear understanding of struc-
tures of the antibiotic bound to both its
target, as well as to the enzyme that
confers resistance by chemical modifica-
tion or breakdown of the active drug. The
availability of these structures enables
the design of improved compounds thatmaintain necessary interactions for the
binding of drug to the target, yet prevent
interactions with the modifying enzymes.
In this issue ofStructure, a report byMorar
et al. (2009) takes us one step closer in this
regardwith the lincosamide antibiotic clin-
damycin (Figure 1).
Clindamycin is a member of the linco-
samide family of antibiotics. Lincosa-
mides are classified with other macrolide
and streptagramin (MLS) antibiotics,
which all share a common binding site
on the 23S rRNA of the 50S subunit of
the bacterial ribosome (Roberts, 2008).
Resistance is often conferred by ribo-
somal methylation catalyzed by members
of the erythromycin ribosome methylase
(erm) enzymes. In modifying the ribosome
target, these enzymes confer resistance
to chemically diverse drugs (Leclercq,
2002). Resistance to the lincosamides is
also provided by chemical modification
of the drugs with either phosphate or
adenylate groups; resistance provided
by these antibiotic-modifying enzymes is
thus limited to chemically similar com-
pounds that are recognized by the
enzyme active site (Leclercq, 2002).
Structures of clindamycin bound to the
ribosome are known (Schlunzen et al.,
2001; Tu et al., 2005), providing an under-
standing of the functional groups on the
drug that is responsible for target binding
and the inhibition of ribosomal translation.
In this issue of Structure, Morar et al.
(2009) provide the structural and mecha-
nistic insights into the enzymatic modifi-
cation of clindamycin. The authors pres-
ent two X-ray structures of LinB, the
lincosamide antibiotic adenylyltransfer-
ase from Enterococcus faecium. The two
models are structurally very similar withStructure 17, December 9, 2009the exception of different ligands bound
in the active site. In one model, using the
methylene-bridged nonhydrolyzable ATP
mimic, AMPCPP, two Mg2+ ions, and
the cognate antibiotic clindamycin, the
authors were able to trap LinB primed for
adenylation of the antibiotic. The active
site of the second model includes pyro-
phosphate, which adopts the same orien-
tation as the b and g phosphates of ATP.
The structures show that LinB is
composed of two domains: an N-terminal
six-strand b sheet surrounded by two
a helices, and a C-terminal a-helical
bundle. The helical domain of one proto-
mer rests in the groove between the two
domains of the partner monomer, forming
a swapped dimer. Catalysis of clindamycin
adenylation occurs in a cleft at the dimer
interface. Clindamycin binds wholly to
one monomer, stacked between the
AMPCPP molecule and the N-terminal
b sheet. Alternatively, residues from both
monomerscontribute toAMPCPPbinding.
One Mg2+ ion is coordinated by the three
phosphates of the nucleotide. Interest-
ingly, a second Mg2+ ion is observed
bridging the a-phosphate and the nucleo-
philic 30-hydroxyl of clindamycin. This
second cation appears to orient the
30-hydroxyl for attack on the a-phosphate
and was not observed in the related struc-
ture of kanamycin nucleotidyl transferase
(Pedersen et al., 1995). This homolog
contains conserved residues at the posi-
tions of the three ligands for the second
Mg2+, raising the possibility that other
members of this family use two ions in the
catalytic mechanism as well.
Structural and kinetic analyses point
to key residues responsible for substrate
binding,specificity, andnucleotidyl transferª2009 Elsevier Ltd All rights reserved 1549
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PreviewsFigure 1. Binding of Clindamycin to Its Target and Resistance Element
Clindamycin, a lincosamide antibiotic, has now been structurally characterized bound to both the 24S rRNA of the ribosome (left), the therapeutic target, as well
as to the LinB (right), the enzyme that catalyzes the inactivation of the antibiotic through an adenylyltransferase reaction.from ATP. Geometry and distance values
for these residues and the active site
ligands, along with product inhibition
studies and solvent isotope effects, point
to a direct in-line adenylation reaction.
These data are also consistent with prior
enzymatic characterization of diverse
members of this family (Gerratana et al.,
2001; Magnet and Blanchard, 2005).
The kinetic characterization, in addition
to structural comparisons using the
distancealignmentmatrixmethod,allowed
Morar et al. (2009) to classify LinB as a
member of the nucleotidyl transferase
superfamily, joining aminoglycoside nucle-
otidyl transferases and nucleotide poly-
merases. This classification further sup-
ports the proposed LinB mechanism, as
several crystal structures of these related
enzymes with characterized mechanisms
have been solved with trapped active site
intermediates bound to conserved resi-
dues (Pedersen et al., 1995).
The structural and mechanistic data
presented by the authors solidify the
evolutionary relationship between antibi-
otic nucleotidyl transferases and the
nucleotide polymerases found throughout
all forms of life. As only a few of the former1550 Structure 17, December 9, 2009 ª2009are known to exist, the relationship
suggests that they evolved in response
to the smallmolecule antibiotics produced
by competing bacteria or even as a self-
defense mechanism within the bacteria
that produce the antibiotics. Resistance
in virulent strains results from the transfer
of these genes from environmental
bacteria to their pathogenic counterparts.
Finally, the authors propose an inter-
esting analogy from the field of cancer
biology. Oncogenes are mutated or
truncated eukaryotic genes, often incor-
porated into cancer-causing viruses, that
have the capability of transforming a
normal cell into a cancerous one. The
wild-type genes from which these onco-
genes evolved are termed proto-onco-
genes. Adopting this nomenclature,
Morar et al. (2009) term the normal bacte-
rial precursors of antibiotic resistance
genes as proto-resistance elements. This
is an intriguing classification that may
lead to new ways of thinking about the
enzymatic strategies that confer resis-
tance. A more complete understanding
of the evolution of enzymes that confer
antibiotic resistance may also contribute
to the design of novel compounds thatElsevier Ltd All rights reservedmaintain therapeutic activity and are less
susceptible to enzymatic degradation.
Hopefully, this study, and others like it,
will result in new strategies to overcome
antibiotic resistance.
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